ASCO 2017 | Combining a PARP and PD-L1 inhibitor to treat prostate cancer

Ravi A. Madan, MD, from the National Cancer Institute, Bethesda, MD, talks to us about current research on PARP inhibitors for the treatment of prostate cancer, presented at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL. He details his team’s current investigation on the combination of a PARP inhibitor, olaparib, and a PD-L1 inhibitor, durvalumab, in the treatment of metastatic castration-resistant prostate cancer and notes that these drugs may have a synergistic effect, although this requires further studies and analyses.